CAS 1056636-07-7

Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, methanesulfonate (1:?)

Description:

Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, methanesulfonate is a complex organic compound characterized by its structural components, which include a benzamide moiety, a cyanomethyl group, and a methanesulfonate salt. This compound features a pyrimidine ring and a morpholine group, contributing to its potential biological activity. The presence of the methanesulfonate indicates that it is a salt form, which can enhance solubility in polar solvents. The compound may exhibit properties such as moderate to high polarity due to the functional groups present, and it may participate in hydrogen bonding due to the amine and sulfonate functionalities. Its molecular structure suggests potential applications in medicinal chemistry, particularly in the development of pharmaceuticals targeting specific biological pathways. However, detailed studies on its pharmacokinetics, toxicity, and specific applications would be necessary to fully understand its characteristics and potential uses in various fields.

Formula: C₂₃H₂₂N₆O₂·xCH₄O₃S

InChI: InChI=1S/C23H22N6O2.CH4O3S/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;1-5(2,3)4/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);1H3,(H,2,3,4)

InChI key: InChIKey=LYIDPXWFFVJQLY-UHFFFAOYSA-N

SMILES: N(C=1N=C(C2=CC=C(C(NCC#N)=O)C=C2)C=CN1)C3=CC=C(C=C3)N4CCOCC4.S(C)(=O)(=O)O

Synonyms:

• Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, methanesulfonate (1:?)

Momelotinib mesylate

CAS: 1056636-07-7

Momelotinib mesylate is a potent, selective inhibitor of PD-L1. It has been shown to inhibit the expression of PD-L1 in vitro and in vivo. Momelotinib mesylate binds to the B7-H1 protein found on cells that line blood vessels, which is a protein target for tumor cells. It also inhibits the proliferation of cancer cells and may lead to their death. Momelotinib mesylate has been approved by the FDA as a treatment method for patients with myelofibrosis who have had no success with other treatments. This drug is given orally and can be used together with other medications such as steroids or erythropoietin. It has been shown to reduce organ damage and improve quality of life in these patients.

Formula: C₂₄H₂₆N₆O₅S

Purity: Min. 95%

Molecular weight: 510.6 g/mol

Ref: 3D-GSB63607

Momelotinib Mesylate

CAS: 1056636-07-7

Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.

Formula: C₂₄H₂₆N₆O₅S

Purity: 98%

Color and Shape: Solid

Molecular weight: 510.57

Ref: TM-T15037